GKA deel 2 college 14

Nabel: Challenges and opportunities for development of an AIDS vaccin HIV 2008 3.

Nabel: Challenges and opportunities for development of an AIDS vaccin ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],HIV 2008 3.

Properties of HIV that hinder vaccine development ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],HIV 2008 3. Walker and Burton, Science 320, 2008, 760-764

Belangrijkste moeilijkheden HIV vaccin (Tabel 1, Nabel) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],HIV 2008 3.

Possible approaches to vaccine development Nabel 2001, Nature 410, 1002-1006 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],HIV 2008 3. CTL-eliciting vaccine

Possible approaches to vaccine development Nabel 2001, Nature 410, 1002-1006 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],HIV 2008 3. Antibody-eliciting vaccine

Possible approaches to vaccine development Nabel 2001, Nature 410, 1002-1006 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],HIV 2008 3. Replication- defective viral vaccine

CTL respons Nable, Nature 410, 1002-1006 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],HIV 2008 3.

Replicatie-deficiënt virus (“attenuated”) Nabel 2001 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],HIV 2008 3.

Vectors ( Nabel 2001 ) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],HIV 2008 3.

Choice of immunogen ( Nabel 2001 ) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],HIV 2008 3.

Env en CD4 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],HIV 2008 3.

Interaction of env with antibody b12 Zhou et al., 2007, Nature 445, 732-737 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],HIV 2008 3.

IAVI report, Nov 13, 2007 The STEP-trial ,[object Object],HIV 2008 3.

Adeno-based vaccine aimed at CTL: the STEP-trial HIV 2008 3. Conclusion? Science, 21 Nov 2007 Science 1993

Adeno-based vaccine aimed at CTL: the STEP-trial ,[object Object],[object Object],HIV 2008 3. Conclusion? Science, 21 Nov 2007 Science 1993

AIDS vaccine trial 2003 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],HIV 2008 3.

Resultaten VaxGen 2003: % geïnfecteerd binnen de groep HIV 2008 3. Alle personen Blanken en Hispanic Aziatisch Black Andere minderheden Black/Aziatisch/anderen Placebo Gevaccineerd 5,8 5,7 5,4 6,0 9,9 (17 geïnfecteerden) 3,7 (12 geïnfecteerden) 8,1 (9) 10,0 (2) 2,0 (4) 3,8 (2) 15,0 (6) 8,5 (6)

AIDS vaccine trial Thailand, 2006 J Inf Dis 2006, 194: 1661-1671 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],HIV 2008 3. Added 150307

Resultaten AIDSVAX 2006: % infected HIV 2008 3. % Infected of all persons Placebo 8.6

Resultaten AIDSVAX 2006: % infected HIV 2008 3. % Infected of all persons Placebo Vaccinated 8.6 8.4

Resultaten AIDSVAX 2006: % infected HIV 2008 3. % Infected of all persons Female Placebo Vaccinated 8.6 8.4 4.4 7.9 % Infected females

Vaccine trials in 2006 IAVI data, Jan 2007, [email_address] HIV 2008 3. Added 010207

Some examples of vaccine trials in 2006 IAVI data, Jan 2007, [email_address] HIV 2008 3. Added 010207 ========== Ongoing trials of preventive AIDS vaccins Trial no Title Start date Countries (no of sites) Vaccine name Ag (Clade) Phase III Large trials in high-risk populations to test vaccine efficacy RV 144 A Sanofi-Pasteur trial Oct-03 Thailand (8) Prime: ALVAC-HIV Boost: AIDSVAX B/E Env (B/E); gag/pol, env B/E Phase II Mid-sized trials in low- and high-risk populations to test vaccine safety and immunogenicity IAVI A002 Adeno-associated virus+ HIV genes Nov-05 South-Africa, Uganda, Zambia tgAAC09 Gag, PR,  RT (C)

GKA deel 2 college 14

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Viewers also liked

Viewers also liked (19)

Similar to GKA deel 2 college 14

Similar to GKA deel 2 college 14 (20)

More from Biology, Utrecht University

More from Biology, Utrecht University (20)

GKA deel 2 college 14